These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24387684)

  • 1. New biological treatments for gynecological tumors: focus on angiogenesis.
    Daniele G; Di Maio M; Piccirillo MC; Giordano P; Capuano I; Cecere SC; Bryce JC; Pignata S; Perrone F
    Expert Opin Biol Ther; 2014 Mar; 14(3):337-46. PubMed ID: 24387684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
    Jackson AL; Eisenhauer EL; Herzog TJ
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ledermann JA; Raja FA; Fotopoulou C; Gonzalez-Martin A; Colombo N; Sessa C;
    Ann Oncol; 2013 Oct; 24 Suppl 6():vi24-32. PubMed ID: 24078660
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.
    Wei XW; Zhang ZR; Wei YQ
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1181-92. PubMed ID: 23782133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
    van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
    Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
    Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
    Gadducci A; Lanfredini N; Sergiampietri C
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):113-28. PubMed ID: 26126494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
    Eskander RN; Tewari KS
    Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Therapies for Ovarian Cancer.
    Grunewald T; Ledermann JA
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():139-152. PubMed ID: 28111228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial ovarian cancer: focus on targeted therapy.
    Pliarchopoulou K; Pectasides D
    Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.
    Gómez-Raposo C; Mendiola M; Barriuso J; Hardisson D; Redondo A
    Expert Opin Investig Drugs; 2011 May; 20(5):591-4. PubMed ID: 21452927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
    Marchetti C; Gasparri ML; Ruscito I; Palaia I; Perniola G; Carrone A; Farooqi AA; Pecorini F; Muzii L; Panici PB
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):302-10. PubMed ID: 25783620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epithelial ovarian cancer - a change of paradigm].
    Heinzelmann-Schwarz V
    Ther Umsch; 2011 Oct; 68(10):565-72. PubMed ID: 21968896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapies in epithelial ovarian cancer.
    Teoh DG; Secord AA
    Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis Markers in Gynecological Tumors and Patents for Anti-Angiogenic Approach: Review.
    Abdalla DR; Simoens C; Bogers JP; Murta EF; Michelin MA
    Recent Pat Anticancer Drug Discov; 2015; 10(3):298-307. PubMed ID: 26381660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for suppressing angiogenesis in gynecological cancers.
    Ma WW; Jimeno A
    Drugs Today (Barc); 2007 Apr; 43(4):259-73. PubMed ID: 17460787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
    González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.